George  Poste net worth and biography

George Poste Biography and Net Worth

Director of Exelixis
George Poste, DVM, Ph.D., FRS, has been a director since August 2004. Since February 2009, Dr. Poste has been the Chief Scientist at Complex Adaptive Systems Initiative and Regents’ Professor and Del E. Webb Professor of Health Innovation at Arizona State University. From May 2003 to February 2009, Dr. Poste served as the director of the Biodesign Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare, since 2000. From 1992 to 1999, he was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company (later merged into GlaxoSmithKline plc).

What is George Poste's net worth?

The estimated net worth of George Poste is at least $5.86 million as of November 1st, 2024. Dr. Poste owns 169,020 shares of Exelixis stock worth more than $5,856,543 as of November 20th. This net worth estimate does not reflect any other investments that Dr. Poste may own. Learn More about George Poste's net worth.

How do I contact George Poste?

The corporate mailing address for Dr. Poste and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on George Poste's contact information.

Has George Poste been buying or selling shares of Exelixis?

Over the course of the past ninety days, George Poste has sold $1,020,000.00 in Exelixis stock. Most recently, George Poste sold 30,000 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $34.00, for a transaction totalling $1,020,000.00. Following the completion of the sale, the director now directly owns 169,020 shares of the company's stock, valued at $5,746,680. Learn More on George Poste's trading history.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.

Are insiders buying or selling shares of Exelixis?

In the last year, Exelixis insiders bought shares 4 times. They purchased a total of 735,409 shares worth more than $15,270,038.49. In the last year, insiders at the biotechnology company sold shares 22 times. They sold a total of 783,864 shares worth more than $21,654,310.33. The most recent insider tranaction occured on November, 18th when EVP Patrick J Haley sold 41,588 shares worth more than $1,428,963.68. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.

Information on this page was last updated on 11/18/2024.

George Poste Insider Trading History at Exelixis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2024Sell30,000$34.00$1,020,000.00169,020View SEC Filing Icon  
8/8/2024Sell33,725$26.89$906,865.25199,020View SEC Filing Icon  
5/21/2024Sell11,686$20.96$244,938.56213,907View SEC Filing Icon  
11/29/2022Sell40,000$16.68$667,200.00193,189View SEC Filing Icon  
8/16/2019Sell25,000$20.50$512,500.00View SEC Filing Icon  
8/9/2019Sell20,000$20.60$412,000.00View SEC Filing Icon  
3/29/2019Sell3,860$23.89$92,215.40View SEC Filing Icon  
2/28/2018Sell15,000$26.26$393,900.00View SEC Filing Icon  
3/2/2017Sell76,250$22.53$1,717,912.5086,405View SEC Filing Icon  
See Full Table

George Poste Buying and Selling Activity at Exelixis

This chart shows George Poste's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exelixis Company Overview

Exelixis logo
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $34.47
Low: $34.43
High: $34.91

50 Day Range

MA: $29.55
Low: $25.39
High: $36.25

2 Week Range

Now: $34.47
Low: $19.20
High: $36.60

Volume

195,664 shs

Average Volume

2,071,436 shs

Market Capitalization

$9.84 billion

P/E Ratio

22.10

Dividend Yield

N/A

Beta

0.51